Mechanisms of action of glatiramer acetate in the treatment of multiple sclerosis

William Sheremata, Yesica Campos

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter is arranged with three sections. The introduction (. Section 1) includes subsections dealing with the history of experimental allergic encephalomyelitis (EAE) and of the development of copolymer ?1, which led to the development of glatiramer acetate as a pharmacological product. Section 2 introduces glatiramer as an immunomodulator, with two subsections. The first outlines the impact on adaptive immune responses, and the second, the so-called "shift" from Th1 to Th2 helper T cell responses. Section 3 deals with the drug as a neuroprotective agent. The first subsection deals with induction of neurotrophic molecules by glatiramer and the second deals with the drugs impact on the innate immune system; a new focus for research on mechanisms of "switching off" damage by macrophages and microglial cells and "turning on" repair and regeneration of axons and myelin. Figures 1 and 2 show the relationships of the elements of immune function discussed in this chapter.

Original languageEnglish (US)
Title of host publicationMultiple Sclerosis: A Mechanistic View
PublisherElsevier Inc.
Pages339-363
Number of pages25
ISBN (Electronic)9780128010051
ISBN (Print)9780128007631
DOIs
StatePublished - Jan 1 2015

Fingerprint

Multiple Sclerosis
Th2 Cells
Autoimmune Experimental Encephalomyelitis
Immunologic Factors
Neuroprotective Agents
Adaptive Immunity
Myelin Sheath
Helper-Inducer T-Lymphocytes
Pharmaceutical Preparations
Axons
Regeneration
Immune System
History
Macrophages
Pharmacology
Research
Glatiramer Acetate

Keywords

  • Copolymer
  • Mechanisms of disease
  • Multiple sclerosis
  • Myelin basic protein

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sheremata, W., & Campos, Y. (2015). Mechanisms of action of glatiramer acetate in the treatment of multiple sclerosis. In Multiple Sclerosis: A Mechanistic View (pp. 339-363). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-800763-1.00014-2

Mechanisms of action of glatiramer acetate in the treatment of multiple sclerosis. / Sheremata, William; Campos, Yesica.

Multiple Sclerosis: A Mechanistic View. Elsevier Inc., 2015. p. 339-363.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sheremata, W & Campos, Y 2015, Mechanisms of action of glatiramer acetate in the treatment of multiple sclerosis. in Multiple Sclerosis: A Mechanistic View. Elsevier Inc., pp. 339-363. https://doi.org/10.1016/B978-0-12-800763-1.00014-2
Sheremata W, Campos Y. Mechanisms of action of glatiramer acetate in the treatment of multiple sclerosis. In Multiple Sclerosis: A Mechanistic View. Elsevier Inc. 2015. p. 339-363 https://doi.org/10.1016/B978-0-12-800763-1.00014-2
Sheremata, William ; Campos, Yesica. / Mechanisms of action of glatiramer acetate in the treatment of multiple sclerosis. Multiple Sclerosis: A Mechanistic View. Elsevier Inc., 2015. pp. 339-363
@inbook{6cd43250912f447c8a63ed77103ac867,
title = "Mechanisms of action of glatiramer acetate in the treatment of multiple sclerosis",
abstract = "This chapter is arranged with three sections. The introduction (. Section 1) includes subsections dealing with the history of experimental allergic encephalomyelitis (EAE) and of the development of copolymer ?1, which led to the development of glatiramer acetate as a pharmacological product. Section 2 introduces glatiramer as an immunomodulator, with two subsections. The first outlines the impact on adaptive immune responses, and the second, the so-called {"}shift{"} from Th1 to Th2 helper T cell responses. Section 3 deals with the drug as a neuroprotective agent. The first subsection deals with induction of neurotrophic molecules by glatiramer and the second deals with the drugs impact on the innate immune system; a new focus for research on mechanisms of {"}switching off{"} damage by macrophages and microglial cells and {"}turning on{"} repair and regeneration of axons and myelin. Figures 1 and 2 show the relationships of the elements of immune function discussed in this chapter.",
keywords = "Copolymer, Mechanisms of disease, Multiple sclerosis, Myelin basic protein",
author = "William Sheremata and Yesica Campos",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/B978-0-12-800763-1.00014-2",
language = "English (US)",
isbn = "9780128007631",
pages = "339--363",
booktitle = "Multiple Sclerosis: A Mechanistic View",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Mechanisms of action of glatiramer acetate in the treatment of multiple sclerosis

AU - Sheremata, William

AU - Campos, Yesica

PY - 2015/1/1

Y1 - 2015/1/1

N2 - This chapter is arranged with three sections. The introduction (. Section 1) includes subsections dealing with the history of experimental allergic encephalomyelitis (EAE) and of the development of copolymer ?1, which led to the development of glatiramer acetate as a pharmacological product. Section 2 introduces glatiramer as an immunomodulator, with two subsections. The first outlines the impact on adaptive immune responses, and the second, the so-called "shift" from Th1 to Th2 helper T cell responses. Section 3 deals with the drug as a neuroprotective agent. The first subsection deals with induction of neurotrophic molecules by glatiramer and the second deals with the drugs impact on the innate immune system; a new focus for research on mechanisms of "switching off" damage by macrophages and microglial cells and "turning on" repair and regeneration of axons and myelin. Figures 1 and 2 show the relationships of the elements of immune function discussed in this chapter.

AB - This chapter is arranged with three sections. The introduction (. Section 1) includes subsections dealing with the history of experimental allergic encephalomyelitis (EAE) and of the development of copolymer ?1, which led to the development of glatiramer acetate as a pharmacological product. Section 2 introduces glatiramer as an immunomodulator, with two subsections. The first outlines the impact on adaptive immune responses, and the second, the so-called "shift" from Th1 to Th2 helper T cell responses. Section 3 deals with the drug as a neuroprotective agent. The first subsection deals with induction of neurotrophic molecules by glatiramer and the second deals with the drugs impact on the innate immune system; a new focus for research on mechanisms of "switching off" damage by macrophages and microglial cells and "turning on" repair and regeneration of axons and myelin. Figures 1 and 2 show the relationships of the elements of immune function discussed in this chapter.

KW - Copolymer

KW - Mechanisms of disease

KW - Multiple sclerosis

KW - Myelin basic protein

UR - http://www.scopus.com/inward/record.url?scp=85006255983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006255983&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-800763-1.00014-2

DO - 10.1016/B978-0-12-800763-1.00014-2

M3 - Chapter

SN - 9780128007631

SP - 339

EP - 363

BT - Multiple Sclerosis: A Mechanistic View

PB - Elsevier Inc.

ER -